Royal Philips (NYSE:PHG) announced today, December 15, 2025, that it has reached an agreement to acquire SpectraWAVE, a Bedford, Massachusetts-based innovator in intravascular imaging and physiological assessment.
The strategic acquisition will immediately fortify Philips’ portfolio for interventional cardiology by incorporating SpectraWAVE's advanced, AI-enabled technologies.
The deal centers on two key product lines developed by SpectraWAVE: the HyperVue Imaging System, which combines DeepOCT (Deep Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) for detailed coronary plaque assessment, and X1-FFR, an angiography-derived, Artificial Intelligence (AI)-enabled Fractional Flow Reserve (FFR) software solution.
The integration will see these new capabilities merged with Philips’ established Azurion image-guided therapy platform, alongside existing devices such as the Eagle Eye Platinum IVUS and OmniWire iFR.
This move aims to create a more comprehensive and streamlined toolkit for clinicians treating coronary artery disease.
While financial terms of the agreement were not disclosed, the acquisition brings on SpectraWAVE’s team of approximately 70 employees.